Synedgen
Claremont, California, United States · Healthcare, Health Care · 20 employees
Synedgen, Inc. is a biotechnology company developing Multivalent Innate Immune Signaling Target (MIIST) therapeutics that modulate and enhance the innate immune system. The company’s lead development candidate is MIIST305, an oral, glycocalyx targeted induction and maintenance therapy for ulcerative colitis (UC). With US Government support, MIIST305 is also being developed in parallel as a medical
Funding history
- Seed — $1.8M — Oct 2024
- Seed — $3.0M — Sep 2017
- Venture - Series Unknown — $6.0M — Apr 2016
Recent signals
- Jul 03, 2025: Synedgen Signs $119 Million Contract with BARDA for MIIST305 Development
- Jul 02, 2025: Synedgen Promotes Dr. Laura Saward to Chief Executive Officer and Appoints Dr. Kenton Gregory as Chief Medical Officer
- Feb 10, 2025: Synedgen Appoints Dr. Laura Saward, PhD, as Chief Scientific Officer
- Oct 15, 2024: Synedgen Receives $119 Million Contract from BARDA to Develop MIIST305 as Medical Countermeasure for Gastrointestinal Acute Radiation Syndrome
- Oct 01, 2024: Raised $1.8M in Seed
- Sep 12, 2017: Raised $3.0M in Seed
- Apr 27, 2016: Raised $6.0M in Venture - Series Unknown
See plans & pricing → Track Synedgen’s funding, hiring, and signals — with verified contacts — on Fundz.